Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut allergic children<\/a> Jun 2023 [Kim, Keet, Virkud, Penumarti, Smeekens, Guo, Yue, Kulis, Burks]\n The SunBEAm birth cohort: Protocol design<\/a> Aug 2023 [Keet, Kim]\n Environmental Exposure to Foods as a Risk Factor for Food Allergy<\/a> Aug 2023 [Turner, Smeekens]\n A single priming event prevents oral tolerance to peanut<\/a> Sep 2023 [Smeekens, Kesselring, Turner, Kulis, Moran]\n Desensitization and remission after peanut sublingual immunotherapy in 1-to-4-year-old peanut-allergic children: A randomized, placebo-controlled trial<\/a> Oct 2023 [Kim, Keet, Virkud, Herlihy, Smeekens, Guo, Yue, Penumarti, Kulis, Burks]\n Frequency and predictors of multisystem reactions to peanut in infant oral food challenges<\/a> Oct 2023 [Keet]\n IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis<\/a> Nov 2023 [Keet]\n Home Introduction of Baked Egg after Oral Food Challenge<\/a> Oct 2022 [Keet]\n Novel peanut-specific human IgE monoclonal antibodies enable screens for inhibitors of the effector phase in food allergy<\/a> Sept 2022 [Burks, Guo, Iweala, Kulis, Suber, Ye, Zhang]\n Preventing allergies through the skin<\/a> Sept 2022 [Keet, Winslow]\n Allergen recognition by specific effector Th2 cells enables IL-2-dependent activation of regulatory T-cell responses in humans<\/a> Sept 2022 [Burks]\n Longitudinal disease-associated gut microbiome differences in infants with food protein-induced allergic proctocolitis<\/a> Sept 2022 [Virkud]\n Peanut anaphylaxis in 2022: Decoupling epinephrine usage from emergency department evaluation<\/a> Sept 2022 [Kim, Winslow]\n Treatment for food allergy: Current status and unmet needs<\/a> Aug 2022 [Kim]\n Peanut-Specific IgG4 and IgA in Saliva Are Modulated by Peanut Oral Immunotherapy<\/a> Aug 2022 [Burks, Kim, Kulis, Smeekens]\n A “LEAP” forward in understanding immune mechanisms of oral tolerance to peanut<\/a> Aug 2022 [Kulis, Moran]\n Single-dose AAV vector gene immunotherapy to treat food allergy<\/a> July 2022 [Kulis]\n Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results<\/a> July 2022 [Kim]\n Targeting CD22 on memory B cells to induce tolerance to peanut allergens<\/a> July 2022 [Burks, Kulis, Hardy, Smeekens]\n Evaluation of a group visit model for access to infant and toddler oral food challenges<\/a> Jun 2022 [Virkud]\n Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis<\/a> Jun 2022 [Keet]\n Comprehensive home environmental intervention did not reduce allergen concentrations or controller medication requirements among children in Baltimore<\/a> Jun 2022 [Keet]\n Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy<\/a> Jun 2022 [Kim]\n Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials<\/a> Jun 2022 [Burks]\n Kinetics of basophil hyporesponsiveness during short-course peanut oral immunotherapy<\/a> Jun 2022 [Burks, Guo, Hamilton, Herlihy, Keet, Kim, Kulis, Li, Smeekens, Ye, Yue]\n Prospective associations between acid suppressive therapy and food allergy in early childhood<\/a> May 2022 [Virkud]\n Efficacy and safety of baked milk oral immunotherapy in children with severe milk allergy: A randomized, double-blind, placebo-controlled phase 2 trial<\/a> Apr 2022 [Keet]\n Effective methods of clinical education<\/a> Mar 2022 [Kim]\n The year in food allergy<\/a> Mar 2022 [Keet]\n Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts<\/a> Apr 2022 [Burks, Kim]\n Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study<\/a> Jan 2022 [Burks, Kim, Kulis]\n Bringing the Next Generation of Food Allergy Diagnostics Into the Clinic<\/a> Jan 2022 [Kulis]\n Mouse Models of Food Allergy in the Pursuit of Novel Treatment Modalities<\/a> Dec 2021 [Kulis, Smeekens]\n Mapping Sequential IgE-Binding Epitopes on Major and Minor Egg Allergens<\/a> Nov 2021 [Burks]\n The airway as a route of sensitization to peanut: An update to the dual allergen exposure hypothesis<\/a> Sept 2021 [Kulis, Moran, Smeekens]\n Heterogeneity in Parent Preferences for Peanut Desensitization Therapy<\/a> Sept 2021 [Kim]\n Caregiver perceptions and attitudes associated with oral immunotherapy on social media<\/a> Sept 2021 [Keet]\n Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study<\/a> May 2021 [Burks]\n Shorter “time to peanut introduction” can prevent peanut allergy and avert false Ara h 2 screening results in infants<\/a> May 2021 [Iglesia, Kim]\n Increasing diversity in peanut oral immunotherapy research and accessibility<\/a> May 2021 [Kim]\n Epicutaneous immunotherapy for treatment of peanut allergy: Follow-up from the Consortium for Food Allergy Research<\/a> Mar 2021 [Burks, Kim]\n Fecal IgA, Antigen Absorption, and Gut Microbiome Composition Are Associated With Food Antigen Sensitization in Genetically Susceptible Mice<\/a> Jan 2021 [Burks, Hinton, Kesselring, Kulis, Smeekens, Steinbach]\n Timing of exposure to environmental adjuvants is critical to mitigate peanut allergy<\/a> Jan 2021 [Kulis, Moran, Smeekens]\n Current Insights into Immunotherapy Approaches for Food Allergy<\/a> Jan 2021 [Burks, Kim]\n Five-year follow-up of early intervention peanut oral immunotherapy<\/a> Jan 2021 [Barber, Burks, Herlihy, Hamilton, Kim]\n Mechanisms of oral immunotherapy<\/a> Jan 2021 [Barshow, Burks, Kim, Kulis]\n Irradiated Tree Nut Flours for Use in Oral Immunotherapy<\/a> Jan 2021 [Burks, Kesselring, Kim, Kulis, Penumarti]\n Model of Walnut Allergy in CC027\/GeniUnc Mice Recapitulates Key Features of Human Disease<\/a> Dec 2020 [Kesselring, Kulis, Smeekens]\n Strategies for Mast Cell Inhibition in Food Allergy<\/a> Dec 2020 [Iweala, Suber]\n Early epitope-specific IgE antibodies are predictive of childhood peanut allergy<\/a> Nov 2020 [Burks]\n Irradiated Tree Nut Flours for Use in Oral Immunotherapy<\/a> Nov 2020 [Burks, Kesselring, Kim, Kulis, Penumarti, Sheth]\n Content and Performance of the MiniMUGA Genotyping Array: A New Tool To Improve Rigor and Reproducibility in Mouse Research<\/a> Oct 2020 [Burks, Kulis]\n Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy<\/a> Oct 2020 [Burks, Kim]\n Dosing, safety, and quality of life after peanut immunotherapy trials: A long-term follow-up study<\/a> Sept 2020 [Barber, Burks, Herlihy, Kim]\n Timing of exposure to environmental adjuvants is critical to mitigate peanut allergy<\/a> Sept 2020 [Kulis, Smeekens]\n IgE producers in the gut expand the gut’s role in food allergy<\/a> Jul 2020 [Burks, Iweala]\n Food allergy immunotherapy: Oral immunotherapy and epicutaneous immunotherapy<\/a> Jun 2020 [Burks, Kim]\n Legends of allergy and immunology: Hugh A. Sampson<\/a> Jun 2020 [Burks]\n A 5-year summary of real-life dietary egg consumption after completion of a 4-year egg powder oral immunotherapy (eOIT) protocol<\/a> Apr 2020 [Burks, Kim]\n Peanut applied to the skin of nonhuman primates induces antigen-specific IgG but not IgE<\/a> Mar 2020 [Kulis, Smeekens]\n Systematic quantification of the dynamics of newly synthesized proteins unveiling their degradation pathways in human cells<\/a> Mar 2020 [Smeekens]\n Immunotherapy approaches for peanut allergy<\/a> Feb 2020 [Burks, Kim, Patel]\n Evolution of Immune Responses in Food Immunotherapy<\/a> Feb 2020 [Kulis, Smeekens]\n Biomarkers in Food Allergy Immunotherapy<\/a> Dec 2019 [Hardy, Kulis, Smeekens]\n A Novel Allergen-Specific Immune Signature-Directed Approach to Dietary Elimination in Eosinophilic Esophagitis<\/a> Dec 2019 [Burks, Guo, Hamilton, Kulis]\n Evolution of Immune Responses in Food Immunotherapy<\/a> Nov 2019 [Kulis, Smeekens]\n IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy<\/a> Oct 2019 [Burks, Kulis]\n Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization<\/a> Sep 2019 [Burks, Guo, Kim, Kulis, Ye]\n Indoor dust acts as an adjuvant to promote sensitization to peanut through the airway<\/a> Sep 2019 [Kulis, Smeekens]\n Clinical factors associated with peanut allergy in a high-risk infant cohort<\/a> Jul 2019 [Burks]\n Plant cell-made protein antigens for induction of Oral tolerance<\/a> Jun 2019 [Kulis]\n The Effects of Early Nutritional Interventions on the Development of Atopic Disease in Infants and Children: The Role of Maternal Dietary Restriction, Breastfeeding, Hydrolyzed Formulas, and Timing of Introduction of Allergenic Complementary Foods<\/a> Apr 2019 [Burks]\n Hypoallergenic Proteins for the Treatment of Food Allergy<\/a> Feb 2019 [Kulis]\n Dosing and Safety of Peanut Food Equivalents After Immunotherapy Trials<\/a> Feb 2019 [Barber, Burks, Herlihy, Kim]\n Back to Life, Back to Reality \u2013 What Happens after Peanut Immunotherapy? A Long-Term Follow up Study on Perceptions of Safety and Lifestyle<\/a> Feb 2019 [Barber, Burks, Herlihy, Kim]\n The Consortium for Food Allergy Research (CoFAR): The first generation<\/a> Feb 2019 [Burks]\n Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness<\/a> Nov 2018 [Burks, Guo, Hardy, Kulis, Smeekens, Suber]\n AR101 Oral Immunotherapy for Peanut Allergy<\/a> Nov 2018 [Burks, Kim]\n Genetic diversity between mouse strains allows identification of the CC027\/GeniUnc strain as an orally reactive model of peanut allergy<\/a> Oct 2018 [Burks, Guo, Kulis, Smeekens, Ye]\n Antigenic Liposomes for Generation of Disease-specific Antibodies<\/a> Oct 2018 [Hardy, Kulis, Smeekens]\n Adjuvanted Immunotherapy Approaches for Peanut Allergy<\/a> Sep 2018 [Burks, Kulis]\n High- and low-dose oral immunotherapy similarly suppress pro-allergic cytokines and basophil activation in young children<\/a> Sep 2018 [Burks, Guo, Kim, Kulis, Ye, Yue]\n Phenotypic Characterization of Eosinophilic Esophagitis in a Large Multicenter Patient Population from the Consortium for Food Allergy Research<\/a> Aug 2018 [Burks]\n Egg-specific IgE and basophil activation but not egg-specific T-cell counts correlate with phenotypes of clinical egg allergy<\/a> Jul 2018 [Burks]\n A Mouse Model of Peanut Allergy Induced by Sensitization Through the Gastrointestinal Tract<\/a> Jun 2018 [Kulis]\n Single-cell profiling of peanut-responsive T cells in patients with peanut allergy reveals heterogeneous effector T H 2 subsets<\/a> Jun 2018 [Burks]\n Tree nut allergies: Allergen homology, cross-reactivity, and implications for therapy<\/a> Jun 2018 [Kulis, Smeekens]\n Characteristics of Preschool-Aged Children Currently Enrolled in a Phase II Double Blind Placebo Controlled Study of Peanut Sublingual Immunotherapy<\/a> Feb 2018 [Burks, Herlihy, Kim]\n A novel assessment of sustained unresponsiveness (SU) after long term sublingual immunotherapy (SLIT) in peanut allergic children: results of a 4 year phase II clinical trial<\/a> Feb 2018 [Bennick, Burks, Hamilton, Herlihy, Kim]\n Assessing the validity of an IRB approved REDCap web based clinical trials recruitment registry<\/a> Feb 2018 [Bennick, English, Hamilton, Herlihy, Kim]\n Immune mechanisms of oral immunotherapy<\/a> Dec 2017 [Kulis]\n Characterization of the B-cell receptor repertoires in peanut allergic subjects undergoing oral immunotherapy<\/a> Nov 2017 [Burks, Kulis]\n Human CD22 Inhibits Murine B Cell Receptor Activation in a Human CD22 Transgenic Mouse Model<\/a> Sep 2017 [Kulis]\n Effect of endotoxin and alum adjuvant vaccine on peanut allergy<\/a> Sep 2017 [Burks, Kulis]\n Specific allergen profiles of peanut foods and diagnostic or therapeutic allergenic products<\/a> Jul 2017 [Commins, Kulis]\n Controlled Asthma Not Correlated with Respiratory Symptoms During DBPCFCs (Double Blind Placebo Controlled Food Challenges) to Peanut in Children<\/a> Feb 2017 [Bennick, Hamilton, Herlihy, Kim]\n Sublingual Peanut Immunotherapy: Role of Duration and Dose.<\/a> Feb 2017 [Bennick, Burks, Hamilton, Herlihy, Kim]\n Sustained Unresponsiveness After Sublingual Immunotherapy for Peanut-allergic Children<\/a> Feb 2017 [Bennick, Burks, Hamilton, Herlihy, Kim]\n Preparation and Analysis of Peanut Flour Used in Oral Immunotherapy Clinical Trials<\/a> Jan 2017 [ Burks, Kesselring, Kulis, Penumarti]\n Eosinophilic esophagitis during peanut oral immunotherapy with omalizumab<\/a> Dec 2016 [Burks, Kulis]\n Food allergen extracts to diagnose food-induced allergic diseases: How they are made<\/a> Nov 2016 [Burks, Penumarti]\n Mast cell desensitization inhibits calcium flux and aberrantly remodels actin<\/a> Sep 2016 [Burks, Kulis]\n Exploiting CD22 on antigen-specific B cells to prevent allergy to the major peanut allergen Ara h 2<\/a> Aug 2016 [Burks, Kulis]\n Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective<\/a> Aug 2016 [Burks, Guo, Kim, Kulis, Ye]\n Component-resolved analysis of IgA, IgE, and IgG4 during egg OIT identifies markers associated with sustained unresponsiveness<\/a> Jun 2016 [Burks, Kulis]\n Peanut Allergy: New Developments and Clinical Implications<\/a> May 2016 [Commins, Kim, Kulis]\n The Seed Biotinylated Protein of Soybean (Glycine max): A Boiling-Resistant New Allergen (Gly m 7) with the Capacity To Induce IgE-Mediated Allergic Responses<\/a> May 2016 [Burks, Kulis]\n Food-specific IgG 4 is associated with eosinophilic esophagitis<\/a> Apr 2016 [Burks, Guo, Kulis]\n NMR-Based Metabolomics Analysis Reproducibly Identifies Unique Subject-Specific Profiles That Change during Peanut Oral Immunotherapy<\/a> Feb 2016 [Burks, Hamilton, Kulis]\n Basophil Activation and Peanut-Specific IgE Are Not Predictors of Threshold Dose during a Double-Blind Placebo-Controlled Food Challenge (DBPCFC)<\/a> Feb 2016 [Burks, Guo, Hamilton, Kim, Ye]\n Utility of component analyses in subjects undergoing sublingual immunotherapy for peanut allergy<\/a> Feb 2016 [Burks, Kim, Kulis]\n High Rate of Sustained Unresponsiveness with Early-Intervention Peanut Oral Immunotherapy<\/a> Feb 2015 [Burks, Hamilton, Herlihy, Kim, Kulis]\n Peanut Sublingual Immunotherapy (SLIT) Results in Sustained Unresponsiveness in a Subset of Peanut Allergic Children<\/a> Feb 2015 [Burks, Hamilton, Guo, Kim, Kulis]\n Basophil Hyporesponsiveness Following Six Months of Peanut Oral Immunotherapy (OIT) Is Associated with Suppression of Syk Phosphorylation<\/a> Feb 2015 [Burks, Hamilton, Kulis, Yue]\n Novel strategy to create hypoallergenic peanut protein-polyphenol edible matrices for oral immunotherapy<\/a> May 2014 [Burks, Guo, Kulis]\n2022<\/span><\/h2>\n
\n2021<\/span><\/h2>\n
\n2020<\/span><\/h2>\n
\n2019<\/span><\/h2>\n
\n2018<\/span><\/h2>\n
\n2017<\/span><\/h2>\n
\n2016<\/span><\/h2>\n
\n2015<\/span><\/h2>\n
\n2014<\/span><\/h2>\n
\n2013<\/span><\/h2>\n